NMDP-02 is under clinical development by NMD Pharma and currently in Phase II for Spinal Muscular Atrophy (SMA). According to GlobalData, Phase II drugs for Spinal Muscular Atrophy (SMA) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NMDP-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NMDP-02 overview

NMDP-02 is under development for the treatment of spinal muscular atrophy type 3. It acts by targeting chloride channel protein 1 (CLC-1). It is administered through oral route in the form of tablets.

NMD Pharma overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases. It develops novel treatments that strengthen neuromuscular transmission and muscle function. NMD Pharma product pipeline includes NMDP-01 (NMD670), NMDP-02 (NMD670),NMDP-03 (NMD1343),NMDP-04, NMDP-05 and NMDP-06. Its product pipeline treats myasthenia gravis, spinal muscular atrophy, rare neuromuscular disease, scarcopenia and reversal of neuromuscular block. The company carries out translational muscle electrophysiology platform. It also utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases. NMD Pharma is headquartered in Aarhus, Denmark.

For a complete picture of NMDP-02’s drug-specific PTSR and LoA scores, buy the report here.